Skip to main content
Premium Trial:

Request an Annual Quote

Exiqon Posts 17 Percent Revenue Growth for Q3

NEW YORK (GenomeWeb) – Exiqon today reported that its third quarter revenues increased 17 percent year over year to DKK 34.8 million ($5.9 million) from DKK 29.8 million.

The Copenhagen, Denmark-based genomic research products firm said that its research product sales and services were up 7 percent year over year to DKK 26.1 million from DKK 24.3 million. Its services revenue more than doubled to DKK 7.1 million from DKK 3.1 million, driven by next-generation sequencing services that were launched early in 2014 and offsetting declining sales of the firm's miRCURY LNA microRNA Array system.

Exiqon posted a net profit of DKK 1.3 million, or DKK .04 per share, versus a loss of DKK 1.7 million, or DKK .05 per share, for Q3 2013.

The firm's R&D costs dropped 14 percent year over year to DKK 6 million from DKK 7 million, while its SG&A spending climbed 3 percent to DKK 14 million from DKK 13.6 million.

"Our recent growth initiatives now begin to take effect, and I'm optimistic that the new markets we address will allow us to capture double-digit growth in our products and services sales," Exiqon CEO Lars Kongsbak said in a statement.

Exiaon said that its plans to launch new products for RNA sequencing that address a double-digit growing market opportunity in excess of $200 million. It also plans products for RNA functional analysis, a market opportunity it pegged at more than $100 million. The firm said these new products will be supported by advanced bioinformatics tools for mobile devices and cloud computing.
Exiqon finished the quarter with DKK 22 million in cash and cash equivalents.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.